From MarketBeat:



Merus (NASDAQ:MRUS) was downgraded from a “hold” rating to a “sell” rating by equities researchers at StockNews.com on Monday. The company’s stock traded at $27.07 during mid-day trading on Monday, and had a $1.56 billion market capitalization, with a price-to-earnings ratio of -7.20 and a beta of 0.82. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ estimates by $0.30. Merus had a negative return on equity of 63.39% and a negative net margin of 387.00%.

Insider activity at Merus shows that COO Peter B. Silverman sold 22,386 shares of the business’s stock, totaling $559,650, and insiders sold 23,076 shares of company stock worth $576,852 in the last ninety days. 4.30% of the stock is owned by company insiders. Many hedge funds and other institutional investors have added to or reduced their stakes in the stock.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, and its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is currently in phase 2 clinical trials. While Merus currently has a “Buy” rating among analysts, top-rated analysts believe that there are five stocks that are better purchases.



Read more: Merus (NASDAQ:MRUS) Downgraded by StockNews.com